ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells
Advanced endometrial cancer (EC) and melanoma are two malignancies with poor treatment options at advanced stages. CDK4 and CDK6 kinases play a central role in the regulation of cell proliferation by controlling progression through G1/S transition. CDK4/CDK6 inhibitors are currently in clinical trials for advanced ECs, whereas melanoma tumors frequently carry mutations affecting the CDK4/CDK6…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
